Citius Oncology Announced It Has Finalized An Exclusive Agreement With EVERSANA To Support The Q4 2025 U.S. Commercialization Of LYMPHIR

Tenx Keane Acquisition +8.47%
Citius Pharmaceuticals Inc +1.32%

Tenx Keane Acquisition

CTOR

0.70

+8.47%

Citius Pharmaceuticals Inc

CTXR

0.85

+1.32%

EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy

CRANFORD, N.J., Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced it has finalized an exclusive agreement with EVERSANA®, a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology's FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy.

Under the Master Service Agreement, EVERSANA will serve as Citius Oncology's exclusive commercialization partner, providing an integrated suite of pre- and post-launch operations services. These services include medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. As launch preparations advance, additional commercialization services are expected to be integrated.

This agreement marks an expansion of EVERSANA's vital role in advancing Citius Oncology's pre-commercial strategy, building on the foundational work already completed in preparation for the U.S. launch of LYMPHIR.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.